Literature DB >> 20472049

Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.

Yutao Liu1, Jie Pan, Si-Shen Feng.   

Abstract

This work developed a system of nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of anticancer drugs with paclitaxel as a model drug, in which the emphasis was given to the effects of the surfactant type and the optimization of the emulsifier amount used in the single emulsion solvent evaporation/extraction process for the nanoparticle preparation on the particle size, characters and in vitro performance. The drug loaded nanoparticles were characterized by laser light scattering (LLS) for size and size distribution, field-emission scanning electron microscopy (FESEM) for surface morphology, X-ray photoelectron spectroscopy (XPS) for surface chemistry, zetasizer for surface charge, and high performance liquid chromatography (HPLC) for drug encapsulation efficiency and in vitro drug release kinetics. MCF-7 breast cancer cells were employed to evaluate the cellular uptake and cytotoxicity. It was found that phospholipids of short chains such as 1,2-dilauroylphosphatidylocholine (DLPC) have great advantages over the traditional emulsifier poly(vinyl alcohol) (PVA), which is used most often in the literature, in preparation of nanoparticles of biodegradable polymers such as poly(D,L-lactide-co-glycolide) (PLGA) for desired particle size, character and in vitro cellular uptake and cytotoxicity. After incubation with MCF-7 cells at 0.250 mg/ml NP concentration, the coumarin-6 loaded PLGA NPs of DLPC shell showed more effective cellular uptake versus those of PVA shell. The analysis of IC(50), i.e. the drug concentration at which 50% of the cells are killed, demonstrated that our DLPC shell PLGA core NP formulation of paclitaxel could be 5.88-, 5.72-, 7.27-fold effective than the commercial formulation Taxol after 24, 48, 72h treatment, respectively. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472049     DOI: 10.1016/j.ijpharm.2010.05.008

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  24 in total

1.  Preferential cellular uptake of amphiphilic macromolecule-lipid complexes with enhanced stability and biocompatibility.

Authors:  Alexander M Harmon; Melissa H Lash; Sarah M Sparks; Kathryn E Uhrich
Journal:  J Control Release       Date:  2011-04-14       Impact factor: 9.776

2.  Liposome-like Nanostructures for Drug Delivery.

Authors:  Weiwei Gao; Che-Ming J Hu; Ronnie H Fang; Liangfang Zhang
Journal:  J Mater Chem B       Date:  2013-12-28       Impact factor: 6.331

3.  Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.

Authors:  Feihu Wang; Michael Porter; Alexandros Konstantopoulos; Pengcheng Zhang; Honggang Cui
Journal:  J Control Release       Date:  2017-09-25       Impact factor: 9.776

4.  α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.

Authors:  Vanessa Sainz; Liane I F Moura; Carina Peres; Ana I Matos; Ana S Viana; Angela M Wagner; Julia E Vela Ramirez; Teresa S Barata; Manuela Gaspar; Steve Brocchini; Mire Zloh; Nicholas A Peppas; Ronit Satchi-Fainaro; Helena F Florindo
Journal:  Acta Biomater       Date:  2018-06-22       Impact factor: 8.947

5.  Preparation of particulate polymeric therapeutics for medical applications.

Authors:  Jia Zhuang; Ronnie H Fang; Liangfang Zhang
Journal:  Small Methods       Date:  2017-07-25

Review 6.  Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Shigenobu Emoto; Eiji Sunami; Hironori Yamaguchi; Soichiro Ishihara; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2014-02-01       Impact factor: 2.549

7.  Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution.

Authors:  Dongwei Guo; Tianyuzi Li; JoEllyn McMillan; Balasrinivasa R Sajja; Pavan Puligujja; Michael D Boska; Howard E Gendelman; Xin-Ming Liu
Journal:  Nanomedicine (Lond)       Date:  2013-08-01       Impact factor: 5.307

Review 8.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

9.  Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.

Authors:  Yi-Bin Zeng; Zuo-Chong Yu; Yan-Ni He; Tong Zhang; Ling-Bo Du; Yin-Mei Dong; Huai-Wen Chen; Ying-Ying Zhang; Wu-Qing Wang
Journal:  Acta Pharmacol Sin       Date:  2017-12-14       Impact factor: 6.150

10.  Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

Authors:  Ping Ma; Russell J Mumper
Journal:  J Nanomed Nanotechnol       Date:  2013-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.